Loading...

Dicerna Pharmaceuticals

DB:DPL
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DPL
DB
$941M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Dicerna Pharmaceuticals has significant price volatility in the past 3 months.
DPL Share Price and Events
7 Day Returns
-6.2%
DB:DPL
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
17.5%
DB:DPL
-10.2%
DE Biotechs
-6%
DE Market
DPL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dicerna Pharmaceuticals (DPL) -6.2% -1.3% 26.9% 17.5% 179.8% -6.4%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • DPL outperformed the Biotechs industry which returned -10.2% over the past year.
  • DPL outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
DPL
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Dicerna Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Dicerna Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Dicerna Pharmaceuticals.

DB:DPL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DPL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:DPL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Dicerna Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DPL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -54.10 Analyst x1 -50.10
2020 -83.90 Analyst x2 -71.96
2021 -96.95 Analyst x2 -77.01
2022 -41.00 Analyst x2 -30.16
2023 20.80 Analyst x2 14.17
2024 29.70 Est @ 42.8% 18.74
2025 38.62 Est @ 30.03% 22.57
2026 46.76 Est @ 21.09% 25.31
2027 53.70 Est @ 14.83% 26.92
2028 59.31 Est @ 10.45% 27.53
Present value of next 10 years cash flows $-94.00
DB:DPL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $59.31 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$767.26
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $767.26 ÷ (1 + 7.98%)10
$356.19
DB:DPL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-94.00 + $356.19
$262.19
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $262.19 / 68.26
$3.84
DB:DPL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DPL represents 0.8744x of NasdaqGS:DRNA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8744x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 3.84 x 0.8744
€3.36
Value per share (EUR) From above. €3.36
Current discount Discount to share price of €12.06
= -1 x (€12.06 - €3.36) / €3.36
-259%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Dicerna Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dicerna Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dicerna Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DPL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.60
NasdaqGS:DRNA Share Price ** NasdaqGS (2019-04-18) in USD $13.79
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dicerna Pharmaceuticals.

DB:DPL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:DRNA Share Price ÷ EPS (both in USD)

= 13.79 ÷ -1.60

-8.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dicerna Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Dicerna Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Dicerna Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:DPL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
0.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Dicerna Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Dicerna Pharmaceuticals's assets?
Raw Data
DB:DPL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.94
NasdaqGS:DRNA Share Price * NasdaqGS (2019-04-18) in USD $13.79
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:DPL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:DRNA Share Price ÷ Book Value per Share (both in USD)

= 13.79 ÷ 2.94

4.69x

* Primary Listing of Dicerna Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dicerna Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Dicerna Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Dicerna Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Dicerna Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
0.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dicerna Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Dicerna Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Dicerna Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Dicerna Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DPL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DPL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 0.1%
DB:DPL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 30.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DPL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DPL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 102 110 -56 4
2022-12-31 43 27 -105 4
2021-12-31 36 -30 -93 5
2020-12-31 38 -82 -77 7
2019-12-31 39 18 -63 7
DB:DPL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 6 18 -89
2018-09-30 7 -49 -93
2018-06-30 5 -51 -93
2018-03-31 4 -49 -82
2017-12-31 1 -45 -80
2017-09-30 0 -51 -71
2017-06-30 0 -50 -66
2017-03-31 0 -47 -58
2016-12-31 -49 -60
2016-09-30 0 -50 -61
2016-06-30 0 -52 -64
2016-03-31 0 -52 -64

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dicerna Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Dicerna Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DPL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Dicerna Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DPL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.77 -0.07 -1.38 4.00
2022-12-31 -1.41 -0.86 -1.91 4.00
2021-12-31 -1.26 -0.79 -1.97 6.00
2020-12-31 -1.18 -0.53 -1.89 8.00
2019-12-31 -1.07 -0.46 -1.67 8.00
DB:DPL Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.60
2018-09-30 -2.02
2018-06-30 -2.48
2018-03-31 -2.75
2017-12-31 -3.66
2017-09-30 -3.43
2017-06-30 -3.20
2017-03-31 -2.80
2016-12-31 -2.87
2016-09-30 -2.84
2016-06-30 -2.97
2016-03-31 -3.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dicerna Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Dicerna Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dicerna Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Dicerna Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dicerna Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dicerna Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Dicerna Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Dicerna Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Dicerna Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dicerna Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DPL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6.18 -88.85 21.69
2018-09-30 6.91 -93.05 28.01
2018-06-30 5.37 -93.17 26.79
2018-03-31 3.82 -81.52 27.90
2017-12-31 1.03 -80.29 16.84
2017-09-30 0.13 -71.36 17.20
2017-06-30 0.30 -66.39 17.40
2017-03-31 0.30 -58.02 19.36
2016-12-31 -59.51 15.43
2016-09-30 0.16 -61.13 17.90
2016-06-30 0.00 -63.89 18.42
2016-03-31 0.18 -64.45 18.28
2015-12-31 0.18 -62.84 19.24
2015-09-30 0.18 -61.79 19.53
2015-06-30 0.18 -56.04 18.40
2015-03-31 -51.22 18.25
2014-12-31 -48.14 15.65
2014-09-30 -40.28 13.18
2014-06-30 -33.63 10.76
2014-03-31 -27.08 7.53
2013-12-31 -20.91 5.82
2013-09-30 6.25 -13.69 4.65
2013-06-30 6.51 -14.09 4.47
2013-03-31 6.76 -14.16 4.58
2012-12-31 7.02 -14.22 4.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Dicerna Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Dicerna Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Dicerna Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Dicerna Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dicerna Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Dicerna Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dicerna Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dicerna Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dicerna Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dicerna Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Dicerna Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dicerna Pharmaceuticals Company Filings, last reported 3 months ago.

DB:DPL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 200.69 0.00 302.63
2018-09-30 156.38 0.00 180.38
2018-06-30 64.58 8.90 82.30
2018-03-31 87.89 0.00 97.82
2017-12-31 101.09 0.00 113.68
2017-09-30 72.20 0.00 75.92
2017-06-30 85.14 0.00 88.73
2017-03-31 29.09 0.00 32.88
2016-12-31 41.21 0.00 45.87
2016-09-30 53.13 0.00 57.55
2016-06-30 64.97 0.00 69.19
2016-03-31 78.18 0.00 80.65
2015-12-31 91.02 0.00 94.61
2015-09-30 104.28 0.00 94.04
2015-06-30 118.68 0.00 95.01
2015-03-31 86.73 0.00 87.67
2014-12-31 98.34 0.00 96.12
2014-09-30 110.82 0.00 92.89
2014-06-30 120.20 0.00 100.26
2014-03-31 129.33 3.79 133.79
2013-12-31 41.86 4.85 46.60
2013-09-30 48.11 5.88 54.71
2013-06-30 -7.47 9.56 1.84
2013-03-31 -0.14 8.80 3.67
2012-12-31 -0.14 8.80 3.67
  • Dicerna Pharmaceuticals has no debt.
  • Dicerna Pharmaceuticals has no debt compared to 5 years ago when it was 11.3%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Dicerna Pharmaceuticals has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Dicerna Pharmaceuticals has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -20.5% per year.
X
Financial health checks
We assess Dicerna Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dicerna Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Dicerna Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Dicerna Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Dicerna Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Dicerna Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Dicerna Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DPL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DPL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Dicerna Pharmaceuticals has not reported any payouts.
  • Unable to verify if Dicerna Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Dicerna Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Dicerna Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Dicerna Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Dicerna Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dicerna Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dicerna Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Dicerna Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Douglas Fambrough
COMPENSATION $1,237,033
AGE 49
TENURE AS CEO 8.9 years
CEO Bio

Dr. Douglas M. Fambrough, III, Ph.D., is a Co-Founder Dicerna Pharmaceuticals, Inc. and has been its Chief Executive Officer and President since May 2010. Dr. Fambrough served as a Venture Partner at Oxford Bioscience Partners and focused his investments on innovative life science technology companies. Dr. Fambrough joined the Oxford Bioscience Partners in 1999 as an Associate and became a Principal in 2001. He became a Partner in 2005 and served as its General Partner from 2007 to 2010. Previously, Dr. Fambrough spent ten years in academic research as a Genomic Scientist, most recently at the Whitehead/MIT Center for Genome Research. He served as the Chairman of Dicerna Pharmaceuticals, Inc. until July 2009. He has been Director of Dicerna pharmaceuticals, Inc since April 2007. He serves as a Director of Endogeny Bio, Solexa and Sirna Therapeutics, Inc. Dr. Fambrough also represented Oxford as a Board Observer at RibX Pharmaceuticals, Xencor, Inc., Cambrios Technologies, Xantos Biomedicine AG and Avalon Pharmaceuticals. He served as a Director of Solstice Neurosciences and Xencor, Inc. He graduated from Cornell University and obtained a Ph.D. in Genetics from the University of California, Berkeley.

CEO Compensation
  • Douglas's compensation has been consistent with company performance over the past year.
  • Douglas's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Dicerna Pharmaceuticals management team in years:

2.7
Average Tenure
56
Average Age
  • The tenure for the Dicerna Pharmaceuticals management team is about average.
Management Team

Douglas Fambrough

TITLE
Co-Founder
COMPENSATION
$1M
AGE
49
TENURE
8.9 yrs

Bob Brown

TITLE
Chief Scientific Officer & Senior VP
COMPENSATION
$722K
AGE
53
TENURE
7.3 yrs

Ralf Rosskamp

TITLE
Chief Medical Officer
COMPENSATION
$953K
AGE
65
TENURE
1.8 yrs

Mark Behlke

TITLE
Co-Founder & Member of Scientific Advisory Board

John Rossi

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
71

Jack Green

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
64
TENURE
3 yrs

David Miller

TITLE
Senior Vice President of Corporate Operations & Alliance Management
TENURE
2.3 yrs

Rebecca Peterson

TITLE
Head of Corporate Communications
AGE
43
TENURE
0.2 yrs

Regina Paglia

TITLE
Senior Vice President of Human Resources
TENURE
0.2 yrs

Jim Weissman

TITLE
Chief Business Officer
COMPENSATION
$1M
AGE
56
TENURE
7.3 yrs
Board of Directors Tenure

Average tenure and age of the Dicerna Pharmaceuticals board of directors in years:

10.5
Average Tenure
63
Average Age
  • The average tenure for the Dicerna Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

J. Buchi

TITLE
Chairman of the Board
AGE
63
TENURE
0.3 yrs

Douglas Fambrough

TITLE
Co-Founder
COMPENSATION
$1M
AGE
49
TENURE
12 yrs

Mark Behlke

TITLE
Co-Founder & Member of Scientific Advisory Board

John Rossi

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
71
TENURE
10.5 yrs

Martin Freed

TITLE
Independent Director
COMPENSATION
$102K
AGE
57
TENURE
2.8 yrs

Steve Hoffman

TITLE
Director
COMPENSATION
$106K
AGE
64
TENURE
11.4 yrs

Frank McCormick

TITLE
Member of Scientific Advisory Board
AGE
68
TENURE
10.5 yrs

Dennis Langer

TITLE
Director
COMPENSATION
$101K
AGE
66
TENURE
11.4 yrs

Peter Kolchinsky

TITLE
Director
COMPENSATION
$101K
AGE
41
TENURE
5.8 yrs

Adam Koppel

TITLE
Director
COMPENSATION
$145K
AGE
48
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Nov 18 Sell Domain Associates, L.L.C. Company 02. Nov 18 06. Nov 18 -335,000 €12.41 €-3,911,456
05. Nov 18 Sell Domain Associates, L.L.C. Company 30. Oct 18 01. Nov 18 -565,000 €12.56 €-6,773,694
X
Management checks
We assess Dicerna Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dicerna Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company’s development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Details
Name: Dicerna Pharmaceuticals, Inc.
DPL
Exchange: DB
Founded: 2006
$837,069,446
68,264,949
Website: http://www.dicerna.com
Address: Dicerna Pharmaceuticals, Inc.
87 Cambridgepark Drive,
Cambridge,
Massachusetts, 02140,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS DRNA Common Stock Nasdaq Global Select US USD 30. Jan 2014
DB DPL Common Stock Deutsche Boerse AG DE EUR 30. Jan 2014
Number of employees
Current staff
Staff numbers
78
Dicerna Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/20
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.